Hidden Potential of Highly Efficient and Widely Accessible Thrombolytic Staphylokinase
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00159816%3A_____%2F22%3A00077655" target="_blank" >RIV/00159816:_____/22:00077655 - isvavai.cz</a>
Alternative codes found
RIV/00216224:14310/22:00127971
Result on the web
<a href="https://www.ahajournals.org/doi/10.1161/STROKEAHA.122.040219" target="_blank" >https://www.ahajournals.org/doi/10.1161/STROKEAHA.122.040219</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1161/STROKEAHA.122.040219" target="_blank" >10.1161/STROKEAHA.122.040219</a>
Alternative languages
Result language
angličtina
Original language name
Hidden Potential of Highly Efficient and Widely Accessible Thrombolytic Staphylokinase
Original language description
Stroke burden is substantially increasing but current therapeutic drugs are still far from ideal. Here we highlight the vast potential of staphylokinase as an efficient, fibrin-selective, inexpensive, and evolvable thrombolytic agent. The emphasis is escalated by new recent findings. Staphylokinase nonimmunogenic variant was proven noninferior to alteplase in a clinical trial, with decreased risk of intracranial hemorrhage and the advantage of single bolus administration. Furthermore, our detailed kinetic analysis revealed a new staphylokinase limiting bottleneck whose elimination might provide up to 1000-fold higher activity than the clinically approved alteplase. This knowledge of limitations unlocks new possibilities for improvements that are now achievable by the community of protein engineers who have the required expertise and are ready to transform staphylokinase into a powerful molecule. Collectively, the noninferiority and safety of nonimmunogenic staphylokinase together with the newly identified effectivity limitation make staphylokinase a perfect candidate for further exploration, modification, and advancement to make it the next-generation widely accessible thrombolytic drug effectively treating stroke all around the world, including middle- and low-income countries.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30210 - Clinical neurology
Result continuities
Project
Result was created during the realization of more than one project. More information in the Projects tab.
Continuities
P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)
Others
Publication year
2022
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Stroke
ISSN
0039-2499
e-ISSN
1524-4628
Volume of the periodical
53
Issue of the periodical within the volume
10
Country of publishing house
US - UNITED STATES
Number of pages
3
Pages from-to
3235-3237
UT code for WoS article
000856392500041
EID of the result in the Scopus database
—